Rocket Pharmaceuticals (RCKT) Enterprise Value (2014 - 2026)

Rocket Pharmaceuticals has disclosed Enterprise Value across 13 years of filings, most recently posting -$239.2 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$239.2 million, up 24.83% year-over-year; the trailing twelve-month figure through Mar 2026 was -$239.2 million (up 24.83% YoY), and the FY2025 annual result was -$188.9 million, up 49.26% from the prior year.
• Enterprise Value came in at -$239.2 million for Q1 2026 at Rocket Pharmaceuticals, down from -$188.9 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$188.9 million in Q4 2025 to a low of -$626.5 million in Q1 2023.
• The 5-year median for Enterprise Value is -$356.4 million (2022), against an average of -$374.1 million.
• Across the five-year window, Enterprise Value soared 50.99% in 2024 and slumped 82.97% in 2025, its largest moves.
• Rocket Pharmaceuticals' Enterprise Value stood at -$356.4 million in 2022, then fell by 4.71% to -$373.2 million in 2023, then increased by 0.22% to -$372.3 million in 2024, then soared by 49.26% to -$188.9 million in 2025, then declined by 26.59% to -$239.2 million in 2026.
• The last three Enterprise Value figures came in at -$239.2 million (Q1 2026), -$188.9 million (Q4 2025), and -$222.8 million (Q3 2025), per Business Quant data.